Redeye's take is that a typical 510 (k) submission is followed by a 90-120 review time, and this opens up for a launch in late 2021. The main point is that a launch allows XVIVO to start exploring the late 2020 Organ Assist acquisition and the future benefits of hypothermic oxygenated perfusion of the donor's kidney.